135 related articles for article (PubMed ID: 22561633)
1. JAK2 mutation in patients with splanchnic venous thrombosis: a pilot study from India.
Sazawal S; Rathi S; Chikkara S; Chaubey R; Seth T; Saraya A; Das J; Mahapatra M; Saxena R
Indian J Med Res; 2012 Mar; 135(3):429-31. PubMed ID: 22561633
[No Abstract] [Full Text] [Related]
2. The JAK2 rs12343867 CC genotype frequently occurs in patients with splanchnic venous thrombosis without the JAK2V617F mutation: a retrospective study.
Colaizzo D; Tiscia GL; Bafunno V; Amitrano L; Vergura P; Grandone E; Guardascione MA; Margaglione M
J Thromb Haemost; 2010 Feb; 8(2):413-6. PubMed ID: 19922437
[No Abstract] [Full Text] [Related]
3. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
4. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
Kanellopoulou T; Alexopoulou A; Koskinas J
Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
[No Abstract] [Full Text] [Related]
5. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
[No Abstract] [Full Text] [Related]
6. JAK2 mutations across a spectrum of venous thrombosis cases.
Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
[TBL] [Abstract][Full Text] [Related]
7. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
8. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis.
Colaizzo D; Amitrano L; Tiscia GL; Grandone E; Guardascione MA; Margaglione M
Blood; 2007 Oct; 110(7):2768-9. PubMed ID: 17881638
[No Abstract] [Full Text] [Related]
9. JAK2V617F mutation in patients with splanchnic vein thrombosis.
Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis.
Regina S; Herault O; D'Alteroche L; Binet C; Gruel Y
J Thromb Haemost; 2007 Apr; 5(4):859-61. PubMed ID: 17403204
[No Abstract] [Full Text] [Related]
11. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
[TBL] [Abstract][Full Text] [Related]
12. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
[No Abstract] [Full Text] [Related]
13. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
14. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
15. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
Goodyer M; Langabeer SE; Haslam K; Murphy K
Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
[No Abstract] [Full Text] [Related]
16. Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis.
Colaizzo D; Amitrano L; Guardascione MA; Balzano A; Margaglione M
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):245-6. PubMed ID: 18301309
[No Abstract] [Full Text] [Related]
17. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
[No Abstract] [Full Text] [Related]
18. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis.
Colaizzo D; Tiscia GL; Bafunno V; Amitrano L; Vergura P; Lupone MR; Grandone E; Guardascione MA; Margaglione M
Thromb Res; 2011 Sep; 128(3):233-6. PubMed ID: 21497883
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis.
Colaizzo D; Amitrano L; Guardascione MA; Favuzzi G; Tiscia GL; D'Andrea G; Santacroce R; Grandone E; Margaglione M
Thromb Haemost; 2015 Jun; 113(6):1381-2. PubMed ID: 25761617
[No Abstract] [Full Text] [Related]
20. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
